The value and application prospects of heat shock protein 70 in tumor immunotherapy.
- Author:
Fugang ZHANG
1
;
Li JIANG
1
;
Deqiang WANG
2
;
Ablimit MAMATNIYAZ
1
;
Kang SUN
3
,
4
Author Information
1. School of Outstanding Clinician, Jiangsu University, Zhenjiang 212001, China.
2. Department of Chemotherapy, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China.
3. School of Outstanding Clinician, Jiangsu University, Department of Colorectal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China. *Corresponding author, E-mail: doctorsunkang@
4. com.
- Publication Type:English Abstract
- MeSH:
HSP70 Heat-Shock Proteins/metabolism*;
Humans;
Immunotherapy/methods*;
Neoplasms/immunology*;
Animals;
B7-H1 Antigen/metabolism*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(11):1034-1040
- CountryChina
- Language:Chinese
-
Abstract:
Heat shock protein 70 (HSP70), an evolutionarily conserved molecular chaperone, serves as a central regulator within tumor immune networks. This review summarizes the multiple immune regulatory mechanisms mediated by HSP70 through its specific domains: promoting antigen presentation and cross-presentation processes; prolonging immune response duration; regulating innate and adaptive immune responses; and interacting with immune checkpoint molecules like programmed death-1 ligand 1 (PD-L1). In translation of clinical research, HSP70 can serve as a vaccine adjuvant to enhance immunogenicity, while its inhibitors can overcome resistance to immunotherapy. Additionally, membrane-bound HSP70 represents a potential immunotherapeutic target, and its targeting strategies show significant synergistic effects when combined with immune checkpoint inhibitors. However, due to the functional redundancy of the molecular chaperone network, the clinical efficacy of single-agent HSP70 inhibition is limited. In-depth elucidation of HSP70's synergistic regulatory mechanisms within the chaperone interaction network has important implications for developing novel tumor immunotherapy strategies.
